Search research articles
Contact Us
Filters
Showing results (271-280 of 361) with videos related to
Page
of 37
Sort By:
Bone Marrow Transplantation
|
April 22, 2026
Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)
Fabio Andreozzi, Jacques-Emmanuel Galimard, Johan Maertens, et al.
Mbio
|
May 28, 2021
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis
Samuel M Gonçalves, Daniela Antunes, Luis Leite, et al.
Antimicrobial Agents and Chemotherapy
|
February 5, 2020
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
Johan Maertens, Aaron C Logan, Junho Jang, et al.
Journal of Neurology
|
October 31, 2019
Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT
Martin Schmidt-Hieber, Dan Engelhard, Andrew Ullmann, et al.
Bone Marrow Transplantation
|
January 31, 2019
Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres
Hélène A Poirel, Marijke Vanspauwen, Gilles Macq, et al.
Bone Marrow Transplantation
|
August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT
Noureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Bone Marrow Transplantation
|
December 2, 2021
Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
Tomasz Czerw, Simona Iacobelli, Vittoria Malpassuti, et al.
Blood
|
May 28, 2009
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Jean-Luc Harousseau, Giovanni Martinelli, Wieslaw W Jedrzejczak, et al.
The New England Journal of Medicine
|
December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M Marty, Per Ljungman, Roy F Chemaly, et al.
Haematologica
|
March 23, 2023
Graft-<i>versus</i>-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT
Raynier Devillier, Dirk-Jan Eikema, Carlo Dufour, et al.
Page
of 37
Search research articles
Search
Showing results (271-280 of 361) with videos related to
Sort By:
Page
of 37
Bone Marrow Transplantation
|
April 22, 2026
Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)
Fabio Andreozzi, Jacques-Emmanuel Galimard, Johan Maertens, et al.
Mbio
|
May 28, 2021
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis
Samuel M Gonçalves, Daniela Antunes, Luis Leite, et al.
Antimicrobial Agents and Chemotherapy
|
February 5, 2020
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
Johan Maertens, Aaron C Logan, Junho Jang, et al.
Journal of Neurology
|
October 31, 2019
Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT
Martin Schmidt-Hieber, Dan Engelhard, Andrew Ullmann, et al.
Bone Marrow Transplantation
|
January 31, 2019
Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres
Hélène A Poirel, Marijke Vanspauwen, Gilles Macq, et al.
Bone Marrow Transplantation
|
August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT
Noureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Bone Marrow Transplantation
|
December 2, 2021
Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
Tomasz Czerw, Simona Iacobelli, Vittoria Malpassuti, et al.
Blood
|
May 28, 2009
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Jean-Luc Harousseau, Giovanni Martinelli, Wieslaw W Jedrzejczak, et al.
The New England Journal of Medicine
|
December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M Marty, Per Ljungman, Roy F Chemaly, et al.
Haematologica
|
March 23, 2023
Graft-<i>versus</i>-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT
Raynier Devillier, Dirk-Jan Eikema, Carlo Dufour, et al.
Page
of 37